Cargando…
The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction
Introduction Heart failure with reduced ejection fraction (HFrEF) patients are prone to developing ventricular arrhythmias. In the PARADIGM-HF trial, sacubitril-valsartan (SV) showed a reduction in the composite endpoint of death and HF hospitalization in HFrEF patients; subgroup analysis of this tr...
Autores principales: | Medeiros, Paulo, Coelho, Cláudia, Costa-Oliveira, Cátia, Rocha, Sérgia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984117/ https://www.ncbi.nlm.nih.gov/pubmed/36874318 http://dx.doi.org/10.7759/cureus.34508 |
Ejemplares similares
-
Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021) -
Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure
por: Bano, Shehar, et al.
Publicado: (2021) -
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019) -
Efficacy of Sacubitril/Valsartan in the Setting of Acute Heart Failure: A Systematic Review
por: Mohyeldin, Moiud, et al.
Publicado: (2021) -
A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)